These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27267855)

  • 1. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
    Zhao S; Chen C; Chang K; Karnad A; Jagirdar J; Kumar AP; Freeman JW
    Clin Cancer Res; 2016 Nov; 22(22):5592-5604. PubMed ID: 27267855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer.
    Chen C; Wu B; Wang M; Chen J; Huang Z; Shi JS
    PeerJ; 2022; 10():e12728. PubMed ID: 35846884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
    Chen C; Zhao S; Zhao X; Cao L; Karnad A; Kumar AP; Freeman JW
    Cell Death Dis; 2022 Aug; 13(8):682. PubMed ID: 35931675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
    Molejon MI; Tellechea JI; Loncle C; Gayet O; Gilabert M; Duconseil P; Lopez-Millan MB; Moutardier V; Gasmi M; Garcia S; Turrini O; Ouaissi M; Poizat F; Dusetti N; Iovanna J
    Oncotarget; 2015 Apr; 6(10):7408-23. PubMed ID: 25797268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
    Hong SP; Wen J; Bang S; Park S; Song SY
    Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
    Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
    J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
    Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
    Kumar S; Inigo JR; Kumar R; Chaudhary AK; O'Malley J; Balachandar S; Wang J; Attwood K; Yadav N; Hochwald S; Wang X; Chandra D
    Cancer Lett; 2018 Jan; 413():82-93. PubMed ID: 29107110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.
    Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y
    Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
    Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
    Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
    Avan A; Quint K; Nicolini F; Funel N; Frampton AE; Maftouh M; Pelliccioni S; Schuurhuis GJ; Peters GJ; Giovannetti E
    Curr Pharm Des; 2013; 19(5):940-50. PubMed ID: 22973962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.